Newark, New Castle, USA, June 23, 2023 (GLOBE NEWSWIRE) -- Growth Plus Reports estimated the size of the global market for lymphoma treatment in 2022 to be worth US$ 9.76 billion and is expected to increase at a revenue CAGR of 8.9% to reach US$ 21.02 billion by 2031.
Analysis of the global market for lymphoma treatment indicates that during the forecast period, revenue share is likely to increase significantly. The immune system's lymphocytes, which combat infections, originate from the cancerous condition known as lymphoma. The thymus, lymph nodes, spleen, bone marrow, and other organs all contain these cells.
Key Takeaways:
- The increasing number of non-Hodgkin lymphoma patients is driving the market revenue share.
- The development of novel immune checkpoint inhibitors is driving the market demand.
- The novel product introductions and approvals are fueling the market revenue expansion.
Get a Sample Copy of the Research Report: https://www.growthplusreports.com/inquiry/request-sample/lymphoma-treatment-market/8879
Lymphoma Treatment Market Scope
| Report Attribute | Details |
| Market Size Value in 2022 | US$ 9.76 billion |
| Revenue Forecast in 2031 | US$ 21.02 billion |
| CAGR | 8.9% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023 to 2031 |
| Historical Year | 2021 |
| Segments Covered | Type, Therapy type, Distribution Channel, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Recent Development in the Lymphoma Treatment Market:
- In January 2022, The European Union authorized the marketing of Breyanzi (lisocabtagene maraleucel), a new gene therapy drug for adult patients with diffuse large B-cell lymphoma.
- In January 2022, Regenerative medicine advanced therapy (RMAT) Designation and Fast Track Designation were given to C-CAR039, a novel autologous bi-specific CAR-T therapy that targets both CD19 and CD20 antigens, by the Food and Drug Administration (FDA) for treating patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL).
Competitive Landscape
A list of the prominent players operating in the global market for lymphoma treatment includes:
- Genentech Inc. (F. Hoffmann-La Roche Ltd)
- Merck & Co., Inc.
- Spectrum Pharmaceuticals Inc.
- Bayer AG.
- Novartis AG
- Bristol Myers Squibb Company
Market Drivers and Restraints:
The global lymphoma treatment market revenue is driven by the rising geriatric population more susceptible to non-Hodgkin lymphoma and expanding R&D efforts to create new medications for various lymphomas.
However, due to the lower lymphoma treatment rates and high treatment costs, the lymphoma treatment market revenue growth is expected to be restrained.
Market Segmentation:
Segmentation By Type
Based on the type, the non-Hodgkin lymphoma segment dominates the global lymphoma treatment market with the largest revenue share. This sizable revenue share is attributed to the development of innovative treatments for relapsed or refractory HL, the availability of the most successful therapies, the expansion of the labels of existing drugs.
Segmentation By Therapy Type
Based on the therapy type, the immunotherapy segment dominates the global lymphoma treatment market with the largest revenue share. The sizable revenue of this segment is contributed to the global market-leading immunotherapies, such as Yescarta by Kite Pharma, Inc.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/lymphoma-treatment-market/8879
Segmentation By Distribution Channel
Based on the distribution channel, the hospital pharmacies segment accounts for the highest revenue share as most patients suffering from lymphoma are treated and admitted to hospitals for better healthcare facilities and emergency care.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global lymphoma treatment market. This significant regional revenue is attributed to the higher rates of lymphoma prevalence, increased patient awareness of lymphoma treatment, higher uptake of cutting-edge lymphoma therapeutic medications, and higher healthcare costs in the area. Additionally, ongoing R&D by major market players in the form of clinical trials for novel lymphoma medication candidates has expanded the region's market.
Report Coverage
Growth Plus Reports conducted extensive research on the world market for lymphoma treatment. We looked at the basic market traits, important investment spheres, regional growth dynamics, ten years of revenue projections, rival market participants, and mergers and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL LYMPHOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY TYPE
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- GLOBAL LYMPHOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY THERAPY TYPE
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- GLOBAL LYMPHOMA TREATMENT MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8879
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Adenosquamous Carcinoma Treatment Market by Indication (Breast Cancer, Lungs Cancer), Treatment Regime (Monotherapy, Combination Therapy), Therapy (Chemotherapy, Immunotherapy) – Global Outlook & Forecast 2023-2031
Marine Nutraceuticals Market by Product (Omega-3 Fatty Acids, Fucoidan, Seaweeds), Application (Dietary Supplements, Pharmaceuticals), Form (Softgel Capsules, Powders, Liquid), Distribution Channel (Hypermarkets, Specialty Retail Stores) - Global Outlook & Forecast 2023-2031
Sympathomimetic Drugs Market by Type (Direct, Indirect, Mized), Indications (Cardiovascular Diseases, Asthma & COPD), Distribution Channel (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Cortisone Acetate Market by Indication (Rheumatic Diseases, Dermatologic Conditions), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Belladonna Alkaloids Market by Type (Atropine, Hyoscyamine), Application (Gastrointestinal Disorders, Respiratory Disorders, Overactive Bladder), Route of Administration (Oral, Topical), End User (Hospitals, Pharmaceutical Companies)-Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
